Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

The initial findings demonstrated a significant reduction in major adverse cardiovascular events, leading Health Canada to grant the first-ever indication for semaglutide 2.4 mg in individuals ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational ...

Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes. 1 Obesity directly leads to ...